Study of Bleeding With Extended Administration of an Oral Contraceptive

Sponsor
Warner Chilcott (Industry)
Overall Status
Completed
CT.gov ID
NCT00338052
Collaborator
(none)
207
23
11
9
0.8

Study Details

Study Description

Brief Summary

This is an non-comparative study. There is no statistical hypothesis. The effects of extension of treatment on bleeding will be recorded and described.

Condition or Disease Intervention/Treatment Phase
  • Drug: Norethindrone 1 mg / ethinyl estradiol 20 mcg
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
207 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Open-Label Study of Cycle Control With Extended Administration of Norethindrone Acetate 1 mg / Ethinyl Estradiol 20 Mcg Oral Tablets
Study Start Date :
Jun 1, 2006
Actual Primary Completion Date :
May 1, 2007
Actual Study Completion Date :
May 1, 2007

Outcome Measures

Primary Outcome Measures

  1. Number of bleeding/spotting days/episodes per treatment cycle []

Secondary Outcome Measures

  1. Satisfaction []

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy women

  • Age 25-40

  • History of regular cycles

Exclusion Criteria:
  • Current or recent (within 2 months) users of hormonal contraceptives

  • Contraindications for use of hormonal contraception

  • Conditions which affect the absorption or metabolism of steroid hormones

  • BMI > 35

Contacts and Locations

Locations

Site City State Country Postal Code
1 Warner Chilcott Investigational Site Phoenix Arizona United States 85031
2 Warner Chilcott Investigational Site Phoenix Arizona United States 85050
3 Warner Chilcott Investigational Site Tempe Arizona United States 85283
4 Warner Chilcott Investigational Site Carmichael California United States 95608
5 Warner Chilcott Investigational Site Boynton Beach Florida United States 33437
6 Warner Chilcott Investigational Site Leesburg Florida United States 34748
7 Warner Chilcott Investigational Site Miami Florida United States 33143
8 Warner Chilcott Investigational Site Miami Florida United States 33186
9 Warner Chilcott Investigational Site West Palm Beach Florida United States 33401
10 Warner Chilcott Investigational Site Decatur Georgia United States 30034
11 Warner Chilcott Investigational Site Roswell Georgia United States 30075
12 Warner Chilcott Investigational Site Peoria Illinois United States 61615
13 Warner Chilcott Investigational Site Lexington Kentucky United States 40509
14 Warner Chilcott Investigational Site Louisville Kentucky United States 40291
15 Warner Chilcott Investigational Site New Bern North Carolina United States 28562
16 Warner Chilcott Investigational Site Winston Salem North Carolina United States 27103
17 Warner Chilcott Investigational Site Philadelphia Pennsylvania United States 19114
18 Warner Chilcott Investigational Site Greenville South Carolina United States 29607
19 Warner Chilcott Investigational Site Pleasant Grove Utah United States 84062
20 Warner Chilcott Investigational Site Salt Lake City Utah United States 84017
21 Warner Chilcott Investigational Site Sandy Utah United States 84070
22 Warner Chilcott Investigational Site Virginia Beach Virginia United States 23456
23 Warner Chilcott Investigational Site Seattle Washington United States 98105

Sponsors and Collaborators

  • Warner Chilcott

Investigators

  • Study Director: Herman Ellman, MD, Sponsor GmbH

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00338052
Other Study ID Numbers:
  • PR-02306
First Posted:
Jun 20, 2006
Last Update Posted:
May 8, 2008
Last Verified:
May 1, 2008
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 8, 2008